Clinical Trials Logo

Relapsed Lymphoma clinical trials

View clinical trials related to Relapsed Lymphoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01929720 Completed - Depression Clinical Trials

Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors

FOCUS
Start date: August 2011
Phase: N/A
Study type: Interventional

This randomized clinical trial studies a cognitive-behavioral intervention to treat worry, uncertainty, and insomnia in cancer survivors. Counseling may reduce anxiety and insomnia as well as improve the well-being and quality of life of cancer survivors. This study also explores the neuro-immunologic correlates of anxiety and insomnia.

NCT ID: NCT01742988 Completed - Lymphoma Clinical Trials

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Start date: December 2012
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 alterations. Fimepinostat (CUDC-907) is a multi-targeted agent designed to inhibit phosphoinositide 3-kinase (PI3K)and histone deacetylase (HDAC). The study is designed to assess the safety, the maximum tolerated dose, the recommended phase 2 dose (RP2D), pharmacokinetics and the anti-cancer activity of oral fimepinostat in combination with 1 or more anti-cancer regimens.

NCT ID: NCT00054808 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: June 2002
Phase: Phase 2
Study type: Interventional

Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day by continuous IV infusion for 7 consecutive days using a portable infusion pump. Hospitalization is not required. Stable or responding patients will receive additional gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum total of 8 infusions, or 2 cycles after complete remission has been documented.